Literature DB >> 18047961

Active surveillance for favorable risk prostate cancer: rationale, risks, and results.

Laurence Klotz1.   

Abstract

Active surveillance for favorable risk prostate cancer has become increasingly popular in populations where prostate cancer screening is widespread, due to evidence that prostate cancer screening results in the detection of disease that is not clinically significant in many patients (i.e., untreated, would not pose a threat to health). This approach is supported by data demonstrating that patients who fall into the category of clinically insignificant disease can be identified with reasonable accuracy, and that patients who are initially classified as low risk who reclassify over time as higher risk and are then treated more aggressively are in most cases still cured. An active surveillance approach means (1) identifying patients who have a low likelihood of disease progression during their lifetime, based on clinical and pathologic features of the disease and patient age and comorbidity; (2) monitoring closely over time, (3) establishing reasonable criteria for intervention, which will both identify more aggressive disease in a timely fashion, and not result in excessive treatment, and (4) meeting the communication challenge to reduce the psychological burden of living with untreated cancer. The results of active surveillance, the criteria for patient selection, and the appropriate triggers for intervention are reviewed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18047961     DOI: 10.1016/j.urolonc.2007.05.021

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  10 in total

1.  Secretory phospholipase A2-IIa is a target gene of the HER/HER2-elicited pathway and a potential plasma biomarker for poor prognosis of prostate cancer.

Authors:  Leslie Oleksowicz; Yin Liu; R Bruce Bracken; Krishnanath Gaitonde; Barbara Burke; Paul Succop; Linda Levin; Zhongyun Dong; Shan Lu
Journal:  Prostate       Date:  2011-11-29       Impact factor: 4.104

2.  Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance.

Authors:  Ryan K Berglund; Timothy A Masterson; Kinjal C Vora; Scott E Eggener; James A Eastham; Bertrand D Guillonneau
Journal:  J Urol       Date:  2008-09-17       Impact factor: 7.450

3.  Predictive models for worsening prognosis in potential candidates for active surveillance of presumed low-risk prostate cancer.

Authors:  Prasanna Sooriakumaran; Abhishek Srivastava; Paul Christos; Sonal Grover; Maria Shevchuk; Ashutosh Tewari
Journal:  Int Urol Nephrol       Date:  2011-06-26       Impact factor: 2.370

4.  Outcomes after radical prostatectomy among men who are candidates for active surveillance: results from the SEARCH database.

Authors:  Christopher J Kane; Ronald Im; Christopher L Amling; Joseph C Presti; William J Aronson; Martha K Terris; Stephen J Freedland
Journal:  Urology       Date:  2010-04-15       Impact factor: 2.649

5.  [Status of care for prostate cancer in 2008].

Authors:  B Arndt; M Kwiatkowski; F Recker
Journal:  Urologe A       Date:  2008-08       Impact factor: 0.639

6.  Yearly prostate specific antigen and digital rectal examination fluctuations in a screened population.

Authors:  Donna Pauler Ankerst; Ryan Miyamoto; Prakash Vijay Nair; Brad H Pollock; Ian M Thompson; Dipen J Parekh
Journal:  J Urol       Date:  2009-03-14       Impact factor: 7.450

7.  Algorithms, nomograms and the detection of indolent prostate cancer.

Authors:  Monique J Roobol
Journal:  World J Urol       Date:  2008-06-07       Impact factor: 4.226

Review 8.  [Immunohistochemical algorithms in prostate diagnostics: what's new?].

Authors:  G Kristiansen
Journal:  Pathologe       Date:  2009-12       Impact factor: 1.011

9.  Current strategies for monitoring men with localised prostate cancer lack a strong evidence base: observational longitudinal study.

Authors:  C Metcalfe; K Tilling; M Davis; J A Lane; R M Martin; H Kynaston; P Powell; D E Neal; F Hamdy; J L Donovan
Journal:  Br J Cancer       Date:  2009-07-14       Impact factor: 7.640

10.  Defining the optimal treatment strategy for localized prostate cancer patients: a survey of ongoing studies at the National Cancer Institute of Canada Clinical Trials Group.

Authors:  W R Parulekar; M McKenzie; K N Chi; L Klotz; C Catton; M Brundage; K Ding; A Hiltz; R Meyer; F Saad
Journal:  Curr Oncol       Date:  2008-08       Impact factor: 3.677

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.